{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"51"}],"title":"Clinical Benefit"},{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"77"}],"title":"No Clinical Benefit"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"50"},{"groupId":"OG002","value":"128"}],"units":"Participants"}],"description":"Percent of patients with a complete response, partial response or stable disease lasting more than 16 weeks. A complete response per modified Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) is defined as complete disappearance of all target lesions. A partial response is defined as at least 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters. Stable disease is defined as a tumor that does not meet the criteria for progression or for response. A progressively growing tumor must meet the following criteria: a) the target lesions must be greater or equal to 2cm in size and be a new GIST active lesion or b) the target lesions must be expanding on at least 2 sequential imaging studies.","groups":[{"description":"Patients with a PDGFRA D842V mutation, any line of treatment","id":"OG000","title":"Patients With a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have received 1 prior line of therapy","id":"OG001","title":"2L Patients Without a PDGFRA D842V Mutation"},{"description":"Patients that do not have a PDGFRA D842V mutation and have had 2 or more prior lines of therapy","id":"OG002","title":"3L Patients Without a PDGFRA D842V Mutation"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"patients with a starting dose of 300 or 400 mg QD","reportingStatus":"POSTED","timeFrame":"Tumor assessments were performed at screening, Cycle 3 Day 1, then every 2 cycles through Cycle 13, then every 3 cycles thereafter up to approximately 4 years. Each cycle is 28 days.","title":"Clinical Benefit Rate Determined by Central Radiology Assessment Per mRECIST, Version 1.1","type":"SECONDARY","unitOfMeasure":"Participants"}